TELA Bio Appoints Jeffrey Blizard to its Board of Directors
On June 4, 2024, TELA Bio, a medical technology company specializing in soft-tissue reconstruction solutions, announced the appointment of Jeffrey Blizard to its Board of Directors. Blizard is currently the Global Head of Surgical Sales at Abiomed, a medical device company within Johnson & Johnson's MedTech segment. TELA Bio's CEO, Antony Koblish, emphasized Blizard's extensive sales leadership and experience as important to enhancing their sales force. Blizard expressed enthusiasm about joining during a period of significant growth and confident in his ability to contribute to TELA's success.
- Appointment of Jeffrey Blizard, an experienced sales leader, to TELA Bio's Board of Directors.
- Blizard's background includes his role as Global Head of Surgical Sales at Abiomed, part of Johnson & Johnson's MedTech segment.
- TELA Bio's focus on enhancing their sales force aligns with Blizard's expertise.
- CEO Antony Koblish highlighted the potential for Blizard's experience to significantly benefit the company.
- The press release lacks specific financial data or metrics to quantify the impact of the new appointment.
- No immediate strategic plans or business developments were outlined regarding Blizard's appointment.
- The announcement does not address any potential risks or challenges associated with the new appointment.
MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024.
"We are excited to have Jeff join our Board as we continue to develop and optimize our sales force," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Jeff's exceptional sales leadership and extensive experience will be a tremendous asset to our Board of Directors.”
"I am thrilled to join TELA Bio’s Board of Directors during this dynamic period of growth," said Mr. Blizard. "I am confident that my broad range of sales expertise will significantly contribute to the TELA’s continued success."
About Jeffrey Blizard
Mr. Blizard has served as the Global Head of Surgical Sales at Abiomed since 2017. Abiomed develops and manufactures temporary external and implantable mechanical circulatory support devices. Prior to his current role, Mr. Blizard was General Manager of Sales – CT Surgery, Heart Failure, ECMO, and National Director of Sales – CT Surgery/Heart Failure at Abiomed, where he led sales of Impella in the surgical market bringing it from
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Greg Chodaczek
347-620-7010
ir@telabio.com
Media Contact
Lisa Novy-Wikowski
484-354-6782
lnovywikowski@telabio.com
FAQ
Who was appointed to TELA Bio's Board of Directors on June 4, 2024?
What role does Jeffrey Blizard hold at Abiomed?
Which company does Abiomed operate within?
What is the main focus of TELA Bio?
What did TELA Bio's CEO say about Jeffrey Blizard's appointment?
